Wisconsin state budget expands precision medicine in cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

An item in the newly passed Wisconsin state budget will expand a collaborative network of the UW Carbone Cancer Center and cancer doctors around the state to help find treatments matched to the genetic differences in patients’ cancer.

The budget designates $980,000 for the Precision Medicine Molecular Tumor Board to reach all Wisconsin cancer patients who may need a customized approach to their treatment.

The board began work in September 2015 as collaboration between UW Carbone and the state’s largest oncology practices, including Gundersen Health System in La Crosse, Aurora Health Care in Milwaukee, and Green Bay Oncology. More recently, Fox River Hematology/Oncology, ProHealth and ThedaCare have joined.

When a patient needs new treatment options, physicians around the state can request a genetic test and refer the case to the PMMTB, which reviews the findings and identifies treatments that target the mutations.

For example, a drug already approved for melanoma might target the same mutation found in the patient’s lung cancer. In other cases, the board might find a clinical trial of an experimental treatment that matches the patient’s cancer. In the first year, PMMTB found treatment options for a majority of patients whose cases were reviewed.

The new funding will allow the board to:

  • Increase access to precision medicine by supporting hospitals and clinics across the state that are not currently using precision oncology.

  • Establish a state-wide precision medicine database which allows patients, treatments, and outcomes to be tracked, building a knowledge base for future cases. This has potential to benefit cancer patients across the state and the nation.

  • Continue to review novel cases, while being able to respond more quickly to cases in which the mutations fit patterns that have been seen in the past.

  • Provide support for specialized genetic testing for patients, and support patients who cannot afford testing.

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login